NCT03176459 - Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections | Biotech Hunter

Enrollment

186

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

November 20, 2018

Study Completion Date

December 4, 2018

Conditions

C-SectionPain Management

Interventions

DRUG

Exparel + Bupivacaine

EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.

DRUG

Bupivacaine

Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.

Trial Locations (12)

10032

Columbia Universtiy Medical Center, New York

22042

Inova Fairfax Medical Center, Falls Church

26505

West Virginia University School of Medicine, Morgantown

27704

Duke Regional Hospital, Durham

27710

Duke University Medical Center, Durham

48202

Henry Ford Health Systems, Detroit

55455

University of Minnesota, Minneapolis

92354

Loma Linda University, Loma Linda

94305

Stanford University Medical Center, Stanford

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

08901

St. Peter's University Medical Center, New Brunswick